14-15-Dihydro-14beta-hydroxy-[3alpha,16alpha]-eburnamenine-14-carbonic acid methylester (vincamine, Vincapront) and placebo were compared in a double-blind trial, using daily doses of 60 mg p.o. in 30 out-patients suffering from peripheral and mainly centrally induced labyrinthine deafness